Dynamic nature of braf or kras p.G12c mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?

dc.contributor.author	Jiménez Fonseca, Paula
dc.contributor.author	López López, Carlos
dc.contributor.author	Contreras Toledo, D.
dc.date.accessioned	2024-07-11T07:30:59Z
dc.date.available	2024-07-11T07:30:59Z
dc.date.issued	2024
dc.identifier.citation	British Journal of Cancer, 130(5), p. 777-787 (2024); doi:10.1038/s41416-023-02563-w
dc.identifier.issn	0007-0920
dc.identifier.uri	https://hdl.handle.net/10651/73367
dc.description.sponsorship	The study has been funded by Roche and Sanofi Spain.
dc.format.extent	p. 777-787
dc.language.iso	eng
dc.relation.ispartof	British Journal of Cancer
dc.rights	©,
dc.source	Scopus
dc.source.uri	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85181958427&doi=10.1038%2fs41416-023-02563-w&partnerID=40&md5=09be6f4b161eaf6a35fff37847ad4865
dc.title	Dynamic nature of braf or kras p.G12c mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?
dc.type	journal article
dc.identifier.doi	10.1038/s41416-023-02563-w
dc.relation.publisherversion	http://dx.doi.org/10.1038/s41416-023-02563-w

Ficheros en el ítem

Ficheros	Tamaño	Formato	Ver
No hay ficheros asociados a este ítem.